Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
Janni W, Harbeck N, Rack B, Augustin D, Jueckstock J, Wischnik A, Annecke K, Scholz C, Huober J, Zwingers T, Friedl TW, Kiechle M. Janni W, et al. Among authors: wischnik a. Br J Cancer. 2016 Apr 12;114(8):863-71. doi: 10.1038/bjc.2016.82. Epub 2016 Mar 31. Br J Cancer. 2016. PMID: 27031854 Free PMC article. Clinical Trial.
The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E, Singer S, Janni W, Harbeck N, Weissenbacher T, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Fink V, Schwentner L, Eichler M. Leinert E, et al. Among authors: wischnik a. Clin Breast Cancer. 2017 Apr;17(2):100-106. doi: 10.1016/j.clbc.2016.10.008. Epub 2016 Oct 19. Clin Breast Cancer. 2017. PMID: 27884722
Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial.
Eichler M, Singer S, Janni W, Harbeck N, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Scholz C, Fink V, Schwentner L. Eichler M, et al. Among authors: wischnik a. Breast Cancer. 2017 Mar;24(2):319-325. doi: 10.1007/s12282-016-0706-3. Epub 2016 Jun 4. Breast Cancer. 2017. PMID: 27262301 Clinical Trial.
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
BIG 1-98 Collaborative Group; Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS. BIG 1-98 Collaborative Group, et al. N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818. N Engl J Med. 2009. PMID: 19692688 Free PMC article. Clinical Trial.
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.
Schwentner L, Harbeck N, Singer S, Eichler M, Rack B, Forstbauer H, Wischnik A, Scholz C, Huober J, Friedl TW, Weissenbacher T, Härtl K, Kiechle M, Janni W, Fink V. Schwentner L, et al. Among authors: wischnik a. Breast. 2016 Jun;27:69-77. doi: 10.1016/j.breast.2016.03.003. Epub 2016 Apr 4. Breast. 2016. PMID: 27054751 Clinical Trial.
Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer.
Schönherr A, Aivazova-Fuchs V, Annecke K, Jückstock J, Hepp P, Andergassen U, Augustin D, Simon W, Wischnik A, Mohrmann S, Salmen J, Zwingers T, Kiechle M, Harbeck N, Friese K, Janni W, Rack B. Schönherr A, et al. Among authors: wischnik a. Breast Care (Basel). 2012 Aug;7(4):289-95. doi: 10.1159/000341384. Breast Care (Basel). 2012. PMID: 23904831 Free PMC article.
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany.
Dall P, Koch T, Göhler T, Selbach J, Ammon A, Eggert J, Gazawi N, Rezek D, Wischnik A, Hielscher C, Keitel S, Cirrincione U, Hinke A, Feisel-Schwickardi G. Dall P, et al. Among authors: wischnik a. Oncologist. 2017 Feb;22(2):131-138. doi: 10.1634/theoncologist.2016-0193. Epub 2017 Feb 7. Oncologist. 2017. PMID: 28174294 Free PMC article.
70 results